Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Product Launch

18 Nov 2005 07:00

Original Investments PLC18 November 2005 Original Investments PLC ("Original Investments" or "the Company") Commercial product launch from Acrobot Visualisation software, enabling orthopaedic surgeons to producethree-dimensional bone surface models from Computed Tomography (CT) scans forpre-operative surgical planning, is launched today by The Acrobot Company("Acrobot"). Acrobot is a spin-out company from Imperial Innovations, the technologycommercialization company of Imperial College, London, and develops surgicalsystems for minimally-invasive, bone-conserving orthopaedic surgery. TheAIM-quoted company Original Investments (formerly BioProjects International)owns 25% of Acrobot's equity. The new software, called the Acrobot(R) Planner, is Acrobot's first commercialproduct and is being provided free of charge to surgeons who register to use it.Acrobot will receive fees for data preparation and bone modeling. The Acrobot(R) Planner gives the user the ability to visualise a patient's threedimensional bone surface models built from CT scans. The visualisation isinteractive and the user can select and position implant models onto the bones,evaluate the resulting range of motion, and produce reports. "The software will enable surgeons to assess accurately the exact requirementfor each operation and precisely plan the procedure beforehand," says Dr. PaulaGomes, Acrobot's Director of Operations. "It will help to reduce surgicalerrors, surgeon's stress, and overall procedure costs and times. Radiologistswill also use the software to produce enhanced reports." Further uses for the software will be as a powerful tool for teaching and alsogenerating visual material for presentations. Acrobot provides a commercial service for Acrobot(R) Planner users by taking theraw CT DICOM data, segmenting them and building bone surface models from theinformation. The user can import these patient-specific models into thesoftware, and perform hip resurfacing pre-operative surgical planning and/ orimpingement analysis. The data processing service removes the need for the userto be involved in time-consuming routine data preparation tasks. The Acrobot(R) Planner has been developed by the Acrobot team at the company'slaboratories in London's Leathermarket. It is the first of a number of relatedproducts to be produced by Acrobot, which was founded six years ago by ImperialInnovations as a collaboration to combine the skills of clinicians andacademics. Acrobot is initially focusing on developing precision surgical systems forminimally-invasive techniques in knee and hip replacement. With each product theoverall aims are to reduce error, increase accuracy and enable more difficultsculpted surfaces to be achieved for the new generation of 'resurfacing' orpartial joint implants. Products planned for launch in 2006 include the Acrobot(R) Navigation System,which provides visual guidance for the surgeon and is now undergoing regulatoryapproval, and the Acrobot Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. "We are delighted that our faith in Acrobot is beginning to bear commercialfruit," said Terry Bond, managing director of Original Investments. "Four yearsago we were the first investors outside Imperial College to provide seed-cornfunding for the company and we have continued to support it through the variousstages of its development." Further information on Original Investments PLC from Terry Bond, ManagingDirector, 01235 834734. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Nov 20207:00 amRNSDirectorate Change
3rd Nov 20207:00 amRNSPartnership with Take2 Health Limited
26th Oct 20207:00 amRNSHalf-year Trading update
23rd Oct 20207:00 amRNSCQC accreditation
21st Oct 20207:00 amRNSYourgene Genomic Services collaboration with Cytox
12th Oct 20207:00 amRNSElucigene DPYD tests to be used routinely in Wales
8th Oct 20207:00 amRNSStrategic reproductive health partnership in Japan
7th Oct 20207:00 amRNSIONA®Nx awarded contract with St George’s Hospital
5th Oct 20207:00 amRNSShare Incentive Plan
1st Oct 20204:59 pmRNSCorrection: Holding(s) in Company
1st Oct 20203:29 pmRNSHolding(s) in Company
28th Sep 20207:00 amRNSLaunch of Yourgene Genomic Services
25th Sep 20205:28 pmRNSIssue of Share Options
24th Sep 202010:00 amRNSDPD reimbursement in Germany
24th Sep 20207:00 amRNSDirector/PDMR Shareholding
23rd Sep 20205:20 pmRNSExercise of Options
23rd Sep 202012:25 pmRNSDirector/PDMR Shareholding
22nd Sep 20205:14 pmRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Statement
21st Sep 20207:00 amRNSUS distribution agreement for DPYD &other products
9th Sep 20207:00 amRNSAGM update and investor presentation
3rd Sep 20207:00 amRNSIONA® Nx Launch
28th Aug 20207:00 amRNSNotice of AGM & Annual Report 2020
13th Aug 20207:00 amRNSTGA approves IONA® Nx for sale in Australia
11th Aug 20207:00 amRNSAdmission of Company Considerations Shares and TVR
7th Aug 20203:42 pmRNSHolding(s) in Company
7th Aug 20203:25 pmRNSHolding(s) in Company
7th Aug 20209:48 amRNSHolding(s) in Company
5th Aug 20201:15 pmRNSResult of Placing
5th Aug 20207:00 amRNS£16.15m Placing & Close of Accelerated Bookbuild
4th Aug 20205:13 pmRNSProposed Acquisition and Placing
3rd Aug 20207:00 amRNSCE-IVD Mark for Clarigene™ SARS-CoV-2 test
29th Jul 202012:05 pmRNSAppointment of Joint Broker
28th Jul 20207:00 amRNSFinal Results
13th Jul 20201:13 pmRNSNotice of Results
30th Jun 20207:00 amRNSCOVID-19 assay launched
19th Jun 20204:44 pmRNSIssue of Share Options
16th Jun 20207:00 amRNSCollaboration in COVID-19 testing
15th Jun 20207:00 amRNSCE-IVD mark received for Illumina-based IONA® test
26th May 202012:00 pmRNSHolding(s) in Company
26th May 20207:00 amRNSCOVID-19 testing service launch; business update
20th May 20207:00 amRNSExercise of Warrants and Options
20th Apr 20207:00 amRNSYear-end Trading update: Revenues increase 86%
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:36 pmRNSPrice Monitoring Extension
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSPresentation on ‘Adapting during crisis’

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.